HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

lupinifolin

structure in first source

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        lupinifolin: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        lupinifolin: 3

Experts

1.	Joycharat, Nantiya: 1 article (12/2019)
2.	Muangngam, Kanitta: 1 article (12/2019)
3.	Sianglum, Wipawadee: 1 article (12/2019)
4.	Voravuthikunchai, Supayang Piyawan: 1 article (12/2019)
5.	Furukawa, Hiroshi: 1 article (02/2002)
6.	Ichiishi, Eiichiro: 1 article (02/2002)
7.	Ito, Chihiro: 1 article (02/2002)
8.	Itoigawa, Masataka: 1 article (02/2002)
9.	Ju-ichi, Motoharu: 1 article (02/2002)
10.	Nishino, Hoyoku: 1 article (02/2002)

Related Diseases

1.	Infections 12/01/2019 - "This study suggested that lupinifolin is an essential antimicrobial agent that could be useful for the treatment of MDR enterococcal infections."
2.	Carcinogenesis 02/08/2002 - "Furthermore, lupinifolin (5) exhibited a marked inhibitory effect on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test. "
3.	Neoplasms (Cancer) 02/08/2002 - "Furthermore, lupinifolin (5) exhibited a marked inhibitory effect on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test. "
4.	Bacterial Infections (Bacterial Infection) 01/01/2022 - "<b>Conclusion:</b> These results indicated that lupinifolin can potentially be developed as an antibacterial enhancer for the management of biofilm-associated bacterial infections caused by MRSA, in which the current pharmacological treatment is still limited."

Related Drugs and Biologics

1.	Anti-Infective Agents (Microbicides)